AstraZeneca revealed that its coronavirus vaccine candidate delivers the same immune response in older and younger people and that older people are less likely to experience adverse effects. The elderly might benefit the most from the first round of vaccinations, as they're an at-risk category of people for COVID-19 complications. The company did not release a new study about its advanced COVID-19 vaccine candidate. The company resumed the US arm of its massive Phase 3 trial after the study was ...
AstraZeneca revealed that its coronavirus vaccine candidate delivers the same immune response in older and younger people and that older people are less likely to experience adverse effects. The elderly might benefit the most from the first round of vaccinations, as they're an at-risk category of people for COVID-19 complications. The company did not release a new study about its advanced COVID-19 vaccine candidate. The company resumed the US arm of its massive Phase 3 trial after the study was ...
Share this Article
Recommended